Con il tuo consenso utilizziamo analisi limitate e rispettose della privacy per capire quali percorsi di ricerca funzionano. Non usiamo tracker pubblicitari né registrazioni delle sessioni. Puoi modificare questa scelta nelle Preferenze. Leggi la Informativa sulla privacy.
Quote this valuation with its source: Fair value, Potential value and the price at analysis.
FAQ
UNH — frequently asked questions
Is UnitedHealth Group Incorporated overvalued?
In our latest published analysis dated 2026-09-21, UNH looks meaningfully undervalued. The price recorded at analysis is 377 USD versus our fair value of 448 USD; the high endpoint is presented separately as potential value of 578 USD. That implies roughly 18.9% upside to fair value at that date.
Our latest published report, analyzed 2026-09-21, gives UNH a fair value of 448 USD and a potential value of 578 USD. The conclusion is triangulated across multiple valuation models and weighted by reliability for UnitedHealth Group Incorporated's archetype; it is a dated research output, not a live price.
Should I buy UNH now?
Our latest published rating for UNH, analyzed 2026-09-21, is Buy. UnitedHealth Group Incorporated looks meaningfully undervalued at the analysis-date price of 377 USD versus fair value of 448 USD; potential value is 578 USD. This is research for educational purposes, not personalized investment advice.
What are the biggest risks for UNH?
The dedicated bear-case section in our report analyzed 2026-09-21 documents UnitedHealth Group Incorporated's material risks, evidence, thresholds, and thesis-invalidation conditions. Scenario-specific explanations remain in that section so the report does not repeat or decontextualize them elsewhere.
What is UNH's rating?
Our latest published rating for UNH, analyzed 2026-09-21, is Buy, with a published moat assessment of 7/10 (Narrow). It reflects our fair value of 448 USD, the potential value of 578 USD, and the price recorded at analysis (377 USD).
Questo report non è ancora stato tradotto. Aggiorna tra qualche minuto una volta che la coda di traduzione avrà recuperato.
§1 SintesiEN
Risposta in 30 secondiBuy
Prezzo rispetto al valore
Prezzo
$376.90
Fair value
$448.25
Valore potenziale
$578.10
Al
2026-09-18
Perché può funzionare
Accelerating clinical margin recovery in OptumHealth combined with commercial health benefit premium repricing that absorbs medical cost inflation, driving operating margins from 4.24% in FY2025 toward historical levels of 6.50% and expanding fair value toward Potential value of USD 578.10.
We rate UnitedHealth Group a Buy. The company's massive scale in health benefits and integrated pharmacy services positions it for steady cash generation and earnings recovery, offering attractive upside from the report-date price to our Fair value.
Our rating is Buy. For an investor, this means UnitedHealth Group offers an attractive balance of steady compounding and share price appreciation, supported by leading positions in health benefits and healthcare services.
The report was prepared at a price of USD 376.90 on September 18, 2026. This price trades at a 15.92% discount to our Fair value of USD 448.25. If clinical care margins recover faster than expected, the shares could reach Potential value of USD 578.10.4
The main risk that would change our view is regulatory rate pressure from Medicare and Medicaid, which account for 44.0% of consolidated revenue. If federal payment benchmarks are cut or risk-adjustment coding audits tighten, premium yields per member would decline while medical utilization remains elevated. A reader would see this happen through consolidated operating margins dropping below 3.50% and annual free cash flow falling below $12,000M.
The primary reason the investment can work is UnitedHealth's vertically integrated scale across health benefits and pharmacy care. UnitedHealthcare delivered $344.9B in revenue and OptumRx produced $7.19B in operating profit. By combining health insurance with prescription management, the business manages care costs more effectively than pure-play peers. As medical care ratios stabilize and clinic profitability recovers from recent deficits, operating profit and free cash flow will expand, driving per-share value toward our Fair value of USD 448.25.7
Unmatched Scale in Benefits and Pharmacy Care
UnitedHealthcare's $344.9B revenue base and OptumRx's $7.19B operating profit create unmatched contracting scale and lower unit operating costs than managed care peers.7
Strong operating cash flow of $19.7B and free cash flow of $16.1B fund dependable dividends and share repurchases, driving compounding per-share value as operating margins normalize toward historical levels.5,6
Scale and Cost Advantage in Benefits and Care Delivery
UnitedHealthcare generated $344,903M in FY2025 revenue and $9,425M in operating earnings, providing unprecedented purchasing scale and lower administrative unit costs than regional managed care peers.7
Raccomandazione interna
We recommend a Buy because UnitedHealth Group's integrated scale across health benefits and pharmacy services provides durable cash flow to drive share price recovery to our Fair value.
Panoramica dell’azienda
It also offers direct-to-consumer solutions. On January 1, 2026, the company realigned certain of its businesses to respond to changes in the markets the company serves and the opportunities that are emerging as the health system evolves.
Optum Financial, including Optum Bank, which was historically included in Optum Health, will now be included in Optum Insight.
§2 Scenario ribassistaEN
Under persistent CMS statutory reimbursement cuts on the 44.0% government revenue share combined with elevated medical utilization, operating income falls below FY2025 levels of $18,964M. Free cash flow contracts from $16,075M as debt service on $73,328M total debt limits capital return flexibility.
Medical utilization remains elevated, holding consolidated operating margins depressed
OptumHealth capitation contract deficits widen further
The Bear path envisions persistent CMS Medicare Advantage statutory rate cuts, aggressive risk adjustment coding audits, and elevated medical utilization compressing consolidated operating margins. This scenario would be confirmed if medical care ratios remain elevated and clinic operating losses deepen, leading to reduced earnings power.
Come questa tesi può fallire
Severe Medicare Advantage Rate Cuts and Medical Loss Ratio Spike Compress Consolidated Operating Margin Below 3.5%
CMS accounts for 44.0% of consolidated revenue and consolidated operating profit dropped from $32,358M in FY2023 to $18,964M in FY2025 (a 4.24% margin). A further 100-150 bps contraction pushes operating margin below 3.5%.6,7
FV impact
0%
Operating margin 3 points lower throughout
Trigger
Segnali di allerta precoce da monitorare
I cinque sviluppi che indebolirebbero la nostra tesi d'investimento.
01
consolidated_operating_margin
Medical loss ratio spikes and CMS rate reset pressures reducing operating profit below $16.0B across $447.6B revenue.
UnitedHealth Group possesses a narrow economic moat grounded in the structural cost and scale advantages of its dual-platform model spanning UnitedHealthcare and Optum. The combination of health insurance coverage with integrated pharmacy care services and clinical care delivery creates substantial customer switching costs.
High regulatory exposure to government programs where CMS represents 44.0% of revenue caps potential economic rent extraction, bounding the moat rating at narrow despite superior returns over capital costs.
01Scale and Cost Advantage in Benefits and Care Delivery — UnitedHealthcare generated $344,903M in FY2025 revenue and $9,425M in operating earnings, providing unprecedented purchasing scale and lower administrative unit costs than regional managed care peers.Wide
02High Switching Costs via Integrated PBM and Clinical Services — OptumRx delivered $154,726M in revenue and $7,193M in operating income, while OptumInsight generated $19,417M in revenue, embedding software, data analytics, and pharmacy benefit workflows deep within employer and health system operations.
The highlighted cell is Fair value when every assumption sits at its base level ($448.25). Each row and column shows what Fair value becomes when one assumption moves.
Free cash flow to the firm stays positive in the first projected year at $16.0B after modeled reinvestment of $0, with terminal value at 63.0% of enterprise value. A sudden drop in free cash flow is not projected unless capital spending relative to revenue, reinvestment, or gross margin resets materially.
The Base path represents the modal expectation where UnitedHealthcare maintains its market share and core profitability, while OptumHealth gradually narrows operating losses. Under this progression, operating margins trend toward normalized levels, supporting fair value expansion toward $448.25.
In FY2025, UNH allocated capital across $7,916M in common dividends and $5,545M in share repurchases, reducing diluted share count from 938M in FY2023 to 911M in FY2025. Total debt of $73,328M is supported by steady cash generation.
ROIC stood at 9.66% in FY2025, while operating margin rebounded in the first half of 2026, where Q2-2026 YTD operating profit reached $16,981M (a 7.59% operating margin), recovering from the 4.24% operating margin recorded in FY2025.
ROIC of 9.66% comfortably exceeds the computed WACC of 7.43%, creating positive economic profit across the business.
Ponte dei flussi di cassaCome il flusso di cassa operativo è diventato flusso di cassa libero nel FY2025.
StockMarketAgent.AI
Riconciliazione del flusso operativo
Utile netto12,1 Mld USDAmmortamenti e svalutazioni+4,4 Mld USDCompensi basati su azioni+971 Mln USDAltre rettifiche operative+2,3 Mld USDFlusso di cassa operativo19,7 Mld USD
Riconciliazione della liquidità iniziale e finale
Liquidità iniziale25,3 Mld USDFlusso di cassa operativo+19,7 Mld USDFlusso da investimenti−8,7 Mld USDFlusso da finanziamenti−11,6 Mld USDEffetto dei tassi di cambio+40 Mln USDLiquidità finale24,4 Mld USD
UnitedHealth Group Incorporated (UNH) trades at 16.7x forward earnings against a peer median of 12.2x. Its EV/EBITDA of 14.5x compares with a peer median of 10.3x. The comparison uses 4 peers: CVS Health Corporation, Elevance Health Inc., The Cigna Group and Amgen Inc., as of 2026-09-20.
§10 Settore e cicloEN
Fase del ciclo
Contraction
Industry capex-to-revenue benchmark stands at 0.90% and capex-to-depreciation at 0.81, matching UNH's capital spending of $3,622M against $4,361M depreciation in FY2025.
Ciclo rialzista
Favorable demographics driving Medicare Advantage enrollment growth, expanding value-based care adoption, and commercial pricing updates compensating for medical cost trends.
Ciclo ribassista
Tightening CMS statutory reimbursement rates, V28 risk adjustment model coding phase-ins, elevated outpatient utilization, and heightened antitrust scrutiny on PBM practices.
Trend secolari
Trend
Impatto
Nota
Aging US Population and Medicare Advantage Expansion
positive
Long-term demographic growth expands the addressable market for senior care delivery and health benefit plans.
Stricter CMS Risk Adjustment and Reimbursement Scrutiny
negative
Federal rate benchmarks and risk coding adjustments reduce baseline payment growth per Medicare Advantage enrollee.
Payer-Provider Vertical Integration
positive
Coordinating care delivery, pharmacy services, and benefit management lowers total medical costs relative to fragmented peers.
Posizionamento
As the largest managed care organization in the United States, UNH is positioned to capture value-based care volumes while absorbing regulatory margin friction better than smaller peers.
§11 Gestione della posizioneEN
Dimensionamento
4-6%
Reflects the company's defensive mature compounder profile, strong cash generation, and attractive discount to Fair value of $448.25 relative to the report-date price of $376.90, balanced against CMS regulatory concentration risks.4
Rischio
Maintain strict position size discipline capped at 6% of equity portfolio. Rebalance exposure if Medicare Advantage regulatory rate decisions or unexpected medical loss ratio spikes impair forward cash flow generation.
Tranche di ingresso
Livello
Azione
Perché
Below $380.00
Initiate primary tranche (50% of target allocation)
Trades at an attractive discount to Fair value ($448.25) with forward P/E of 16.72x.
Pause new capital additions and conduct a full re-underwrite of long-term margin recovery assumptions.
optumhealth_operating_income
Operating loss at or below -$500M
Demote valuation model multiples and reduce target position sizing by 25%.
§12 Prospettive degli investitoriEN
Value Investor
Buy
Trading at 16.72x forward earnings and a 15.92% discount to our Fair value of USD 448.25, UNH offers an attractive entry into a premier healthcare compounder with strong 1.63x cash conversion.4,6
Growth Investor
Buy
While near-term revenue growth is modest, Optum's clinical expansion and integrated pharmacy services underpin consensus EPS expectations of $22.61 in FY2027, supporting a near-term earnings rebound and long-term recovery as margins normalize.2
Income & Quality Investor
Buy
Disciplined capital allocation returning $7.9B in dividends and $5.5B in repurchases in FY2025, combined with robust free cash flow of $16.1B, offers dependable income and consistent per-share compounding.5
§14 Raccomandazione finaleEN
Azione
Comprare
We recommend a Buy rating on UnitedHealth Group. At the report-date price of USD 376.90, shares trade at a 15.92% discount to our Fair value of USD 448.25, presenting an attractive risk-reward profile for long-term investors.4
The company's core scale across UnitedHealthcare ($344.9B revenue) and OptumRx ($7.19B operating profit) provides defensive cash flow and pricing power. Robust free cash flow of $16.1B supports steady dividend growth and share repurchases.
§15Your notes
Capture your own thesis, position size, and follow-up questions. Stays on this device, only you can see it.
Private notes
Visible only to you. Synced to this device.
0 chars
Sources
The records this analysis drew on, as they stood when it was run.
Not every cited input appears here: internal calculations and intermediate model outputs have no external record, and some citations could not be matched to one.
OptumHealth generated an operating loss of -$278M in FY2025 on $101,957M revenue. If capitation deficits escalate past -$1,000M, the house forecast margin recovery fails completely.7
FV impact
-1.5%
The analyst's bear scenario path and multiple as the base case
UNH trades at 16.72x forward P/E with an 18.0x modeled terminal P/E, while peers trade at CVS 10.42x, ELV 13.91x, and CI 8.23x. A 20% multiple compression to 14.4x aligns UNH with peer levels.3,4
FV impact
-1.9%
Terminal multiple 20% lower
Trigger
Within 24 months
Widening capitation deficits in care delivery clinics failing to absorb provider wage and clinical inflation on $102.0B revenue.
Attuale:-$278M in FY2025
Avviso seat or below -$500M
03
unitedhealthcare_operating_margin
Commercial and Medicare Advantage underwriting margins compressing under elevated medical care ratios, impairing core cash flow.
Limitation: Terminal value is 65% of this model's value, above the 60% level at which the methodology flags concentration; the value leans on the years beyond the explicit forecast.
The Bull path requires OptumHealth care delivery margins to recover rapidly, commercial employer enrollment to gain market share, and effective contract repricing to outpace medical inflation. The reader would see confirmation through consecutive quarters of expanding operating margins in care delivery and accelerating earnings per share growth toward $578.10.
03
Metrica:
OptumHealth Clinical Care Profitability
AttualeOperating at a deficit in the baseline fiscal year under capitation contract pressures.
Perché è importante
Return to positive operating profit is required to reach the long-term consolidated margin target.
04
Metrica:
OptumRx Pharmacy Services Margin Stability
AttualeConsistently profitable and generating reliable operational cash flow.
Perché è importante
Sustains steady fee income and purchasing scale to buffer clinical underwriting volatility.
